Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RANY ABURASHED

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1790909711
CMS profile
127293
Location
OWOSSO, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$70,330.37

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RANY ABURASHED

NPI 1790909711 · CMS profile ID 127293

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

OWOSSO, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790909711?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RANY ABURASHED, NPI 1790909711, CMS profile ID 127293. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790909711?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RANY ABURASHED, NPI 1790909711, CMS profile ID 127293. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790909711?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RANY ABURASHED, NPI 1790909711, CMS profile ID 127293, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1790909711?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $70,330.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–89 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $17.2702/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236259 CMS
Allergan, Inc. $13.4602/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723633137 CMS
GENZYME CORPORATION $330.3902/08/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236385 CMS
GENZYME CORPORATION $214.2502/08/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236389 CMS
GENZYME CORPORATION $9,968.0002/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236394 CMS
GENZYME CORPORATION $99.0002/08/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236397 CMS
GENZYME CORPORATION $60.0002/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236401 CMS
GENZYME CORPORATION $51.8702/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236405 CMS
Teva Pharmaceuticals USA, Inc. $15.9902/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749452925 CMS
Biogen, Inc. $23.4902/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278341 CMS
Novartis Pharmaceuticals Corporation $22.6801/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725484645 CMS
Eisai Inc. $13.2101/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751202987 CMS
EMD Serono, Inc. $3.5401/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271949 CMS
EMD Serono, Inc. $31.7301/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272201 CMS
EMD Serono, Inc. $12.6101/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272443 CMS
EMD Serono, Inc. $15.7701/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272679 CMS
EMD Serono, Inc. $52.5901/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751272931 CMS
EMD Serono, Inc. $12.6301/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751273283 CMS
EMD Serono, Inc. $23.0101/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751273409 CMS
EMD Serono, Inc. $743.2401/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751298427 CMS
EMD Serono, Inc. $292.6701/24/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751270919 CMS
EMD Serono, Inc. $2.8901/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271193 CMS
EMD Serono, Inc. $7.7301/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271445 CMS
EMD Serono, Inc. $82.1701/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751271697 CMS
CATALYST PHARMACEUTICALS, INC. $23.2001/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 730358997 CMS
GENZYME CORPORATION $20.9801/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744236263 CMS
Neurocrine Biosciences, Inc. $16.3201/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748909227 CMS
Novartis Pharmaceuticals Corporation $12.6101/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725484637 CMS
AbbVie Inc. $20.4001/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721662027 CMS
Biogen, Inc. $432.6101/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278343 CMS
Biogen, Inc. $7,088.0001/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278345 CMS
Biogen, Inc. $36.1401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278349 CMS
Biogen, Inc. $196.6401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278353 CMS
Biogen, Inc. $58.9301/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278357 CMS
Biogen, Inc. $117.3301/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278359 CMS
Biogen, Inc. $89.2101/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278361 CMS
Biogen, Inc. $101.8801/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278347 CMS
Biogen, Inc. $196.6401/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278351 CMS
Biogen, Inc. $125.4601/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737278355 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $206,842.22 239
PY2020 $70,330.37 89
PY2021 $89,353.93 71
PY2022 $24,238.49 21
PY2023 $48,798.14 8
PY2024 $753.10 3
PY2025 $102.45 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $36,651.00 25
PY2024 Principal investigator $77,750.37 35
PY2023 Principal investigator $196,590.21 84
PY2022 Recipient $5,041.00 4
PY2022 Principal investigator $274,599.75 160
PY2021 Recipient $1,567.00 2
PY2021 Principal investigator $254,767.89 44
PY2020 Recipient $677.25 3
PY2020 Principal investigator $474,372.43 44
PY2019 Recipient $2,534.48 14
PY2019 Principal investigator $147,763.90 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $8,743.00 12/22/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119877
Principal investigator 1 Janssen Research & Development, LLC $2,122.00 12/17/2025 Non-covered Recipient Entity
Insight Rsrch Inst Inc.
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175233245
Principal investigator 1 GENZYME CORPORATION $83.00 11/24/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119874
Principal investigator 1 GENZYME CORPORATION $498.00 10/14/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119868
Principal investigator 1 GENZYME CORPORATION $55.00 10/14/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119871
Principal investigator 1 GENZYME CORPORATION $8,577.00 10/06/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119866
Principal investigator 1 Janssen Research & Development, LLC $1,286.00 09/19/2025 Non-covered Recipient Entity
Insight Rsrch Inst Inc.
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175233224
Principal investigator 1 GENZYME CORPORATION $118.00 09/15/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119861
Principal investigator 1 GENZYME CORPORATION $83.00 09/15/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119863
Principal investigator 1 Janssen Research & Development, LLC $6.00 07/28/2025 Non-covered Recipient Entity
Insight Rsrch Inst Inc.
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175233238
Principal investigator 1 GENZYME CORPORATION $332.00 07/02/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119838
Principal investigator 1 GENZYME CORPORATION $1,697.00 07/02/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119843
Principal investigator 1 GENZYME CORPORATION $249.00 05/27/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119832
Principal investigator 1 GENZYME CORPORATION $5.00 05/27/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119835
Principal investigator 1 Janssen Research & Development, LLC $1,908.00 05/16/2025 Non-covered Recipient Entity
Insight Rsrch Inst Inc.
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175233216
Principal investigator 1 GENZYME CORPORATION $1,876.00 04/28/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119829
Principal investigator 1 GENZYME CORPORATION $1,100.00 04/07/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119795
Principal investigator 1 GENZYME CORPORATION $100.00 04/07/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119802
Principal investigator 1 GENZYME CORPORATION $1,378.00 04/07/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119811
Principal investigator 1 GENZYME CORPORATION $1,000.00 04/07/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119815
Principal investigator 1 Janssen Research & Development, LLC $1,908.00 02/19/2025 Non-covered Recipient Entity
Insight Rsrch Inst Inc.
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) No dispute reported 06/30/2026 1175233207
Principal investigator 1 GENZYME CORPORATION $415.00 02/18/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119791
Principal investigator 1 GENZYME CORPORATION $799.00 02/18/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119806
Principal investigator 1 GENZYME CORPORATION $1,707.00 01/06/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226119820
Principal investigator 1 GENZYME CORPORATION $606.00 01/06/2025 Non-covered Recipient Entity
Memorial Healthcare
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226119825